论文部分内容阅读
Objective To evaluate the efficacy and safety of a new long-acting β2 agonist hydrochloric bambuterol for treating asthma.Methods Using randomized, single-blind control and open trials, 254 patients were divided into three groups: treatment group (100 cases), control group(50 cases) and open group(104 cases) .The treatment group and the open group were further divided into two subgroups (tablet group and solution group) and were treated with either bambuterol tablet or solution at a dose of 10-20mg, once daily in the evening for 4 weeks and meanwhile dose titration was undertaken.Results The clinical control percentages were 54%, 46% and 49.07%, 62.75%, and the efficacy percentages were 88%, 94% and 92.4%, 92.17% respectively in the treatment subgroups and open subgroups. The lung function had been significantly improved at the end of 2 weeks’ treatment. The dose titration suggests that the proper dose may be 20mg/ day for some asthmatic patients. The incidence of adverse effects was 7.77% in tablet gro
Objective To evaluate the efficacy and safety of a new long-acting β2 agonist calcium bambuterol for treating asthma. Methods Using randomized, single-blind control and open trials, 254 patients were divided into three groups: treatment group (100 cases), control group (50 cases) and open group (104 cases). The treatment group and the open group were divided into two subgroups (tablet group and solution group) and were treated with either bambuterol tablet or solution at a dose of 10-20 mg, once daily in the evening for 4 weeks and meanwhile dose titration was undertaken. Results The clinical control percentages were 54%, 46% and 49.07%, 62.75%, and the activity percentages were 88%, 94% and 92.4%, 92.17% respectively in the treatment of subgroups and open subgroups. The lung function had been significantly improved at the end of 2 weeks’ treatment. The dose titration suggests that the proper dose may be 20mg / day for some asthmatic patients. The incidence of adverse effects was 7.77% in tablet gro